ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconFacebook IconIcon FacebookGoogle Plus IconLayer 1InstagramCreated with Sketch.Linkedin IconIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerIcon Opinion QuotePositive ArrowIcon PrintRSS IconIcon SearchSite TitleTitle ChevronTwitter IconIcon TwitterYoutube Icon
Health Technology

Hanmi Science Co., Ltd.

  • 84,000.00 KRW
  • +200.00
  • +0.24%
  • South Korea
    Apr 20, 2018
  • Ticker
    KRX(008930)
  • Prev. close
    83,800
  • Market cap (KRW)
    5,321.24B
  • Market cap (USD)
    4,985.93M
  • Shares
    63.49M

Company Background

Hanmi Science is a holding company with two core subsidiaries: Hanmi Pharmaceutical, which develops and produces medicines, and Online Pharm, a drug wholesaler. In recent years, the South Korean group has been actively developing new drugs. It has also accelerated overseas expansion, including by setting up a unit in Beijing.

The company's market capitalization puts it in the top tier of South Korean drug companies, alongside Celltrion.

The group was established in 1973 as Hanmi Pharmaceutical. It strengthened its presence in the drug development game in the 2000s. About 20% of sales are reinvested in research and development.

Hanmi has been focusing on clinical trials for diabetes treatments. It expects the diabetes drug market to grow at an average annual pace of over 6% from 2014 to 2023, nearly doubling in size to $42 billion.

The company's operations include original design manufacturing services for major international drugmakers, including France's Sanofi. For this, Hanmi uses a plant in Hwaseong, Gyeonggi Province. It also runs a facility for antibiotics and biotechnology in Pyeongtaek, in the same province.

Hanmi Fine Chemical, another group company, produces active pharmaceutical ingredients for major drugmakers.

In July 2015, Hanmi announced a partnership with German drugmaker Boehringer Ingelheim. The duo aims to develop a pharmaceutical candidate, HM61713, into a new molecularly targeted drug for lung cancer treatment. Hanmi is to put the drug through clinical trials in South Korea, China and Hong Kong, as well as handle sales licensing, production and commercialization in those markets.

Under the deal, Hanmi will start by using $50 million in contract money to conduct clinical development. The South Korean company stands to receive a total of $730 million, based on progress with licensing and other tasks.

Business Summary

Hanmi Science Co., Ltd. is a holding company that engages in the management of its subsidiaries. It is mainly engaged in the manufacturing and selling of pharmaceutical ingredients and intermediates. The company was founded on June 15,1973 and is headquartered in Hwaseong, South Korea.

Financial Highlights

Dec 2017 KRWUSD
Revenue652,324.36M577.01M
Gross Profit28,307.25M25.03M
Operating income12,704.64M11.23M
Income before tax33,398.11M29.54M
Net income30,068.97M26.59M
EBITDA17,388.56M15.38M
Diluted EPS4880.43
Dividends Per Share196.070.17
Total Assets938,783.18M876.91M
Total liabilities273,630.93M255.59M
Total equity665,154.16M621.32M
Operating cash flow-33,466.88M-29.60M
Currency in KRWCurrency in USD

Historical Data

 Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017
Revenue 220,395.81M 532,886.46M 776,628.55M 665,284.66M 652,324.36M
Gross Profit 17,382.74M 18,462.70M 157,090.07M 27,678.49M 28,307.25M
Operating income 6,822.63M 9,293.29M 147,069.05M 15,067.31M 12,704.64M
Income before tax 6,086.63M 10,490.42M 164,384.79M 5,329.86M 33,398.11M
Net income 9,578.32M 21,312.16M 178,520.88M 7,937.68M 30,068.97M
EBITDA 7,901.71M 10,660.00M 149,100.63M 18,272.20M 17,388.56M
Diluted EPS 155.70 346.73 2,902.69 128.27 488
Dividends Per Share 0 0 449.14 419.76 196.07
Total Assets 579,822.99M 742,795.23M 932,024.38M 969,248.66M 938,783.18M
Total liabilities 170,757.23M 325,083.42M 347,774.73M 321,684.81M 273,630.93M
Total equity 407,881.98M 416,055.37M 583,680.58M 645,286.62M 665,154.16M
Operating cash flow -234.78M 5,245.49M 46,927.26M 85,043.35M -33,466.88M
 Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017
Revenue 201.31M 506.22M 686.18M 573.42M 577.01M
Gross Profit 15.87M 17.53M 138.79M 23.85M 25.03M
Operating income 6.23M 8.82M 129.94M 12.98M 11.23M
Income before tax 5.55M 9.96M 145.24M 4.59M 29.54M
Net income 8.74M 20.24M 157.73M 6.84M 26.59M
EBITDA 7.21M 10.12M 131.73M 15.74M 15.38M
Diluted EPS 0.14 0.32 2.56 0.11 0.43
Dividends Per Share 0 0 0.39 0.36 0.17
Total Assets 549.41M 675.79M 794.86M 802.49M 876.91M
Total liabilities 161.80M 295.75M 296.59M 266.33M 255.59M
Total equity 386.48M 378.52M 497.78M 534.26M 621.32M
Operating cash flow -0.21M 4.98M 41.46M 73.30M -29.60M

Valuation Measures

Dec 2017
PER227.45
ROA3.15%
ROE4.58%
Operating margin1.94%
Profit margin4.60%

Key executives

  • Co-President, Chief Executive Officer & Director: Jong-Yoon Lim
  • Co-President & Director: Sae-Chang Kwon
  • Co-President & Director: Jong-Soo Woo
  • Chairman-Executive Board: Sung-Gi Lim
  • Senior Managing Director: Jong-Ho Lim

Shareholders

  • LIM SUNG-GI (34.2%)
  • SHIN DONG-GUK (12.1%)
  • Hanmi IT (6.4%)
  • LIM JONG YOON (3.6%)
  • LIM JU-HYUN (3.5%)
  • LIM JONG-HOON (3.1%)
  • LIM JIN-HEE (2.2%)
  • Hanmi Science Co., Ltd. (2.1%)
  • SONG YOUNG-SOOK /HANMI/ (1.2%)
  • LIM JONG-HO /HANMI SCIENCE/ (1.1%)

Contact Details

  • Website:http://www.hanmi.co.kr
  • Address: 214 Muha-ro, Paltan-myeon, Hwaseong, 18536, South Korea
  • Phone: +82.31.410.9114

Related Companies

  • Online Pharm. Co., Ltd.

Competitors

  • HUONS CO., LTD
  • IL DONG PHARMACEUTICAL CO., LTD.
Last Updated on 20 Apr, 2018

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

Get unlimited access
NAR site on phone, device, tablet

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

3 months for $9

Get unlimited access
NAR site on phone, device, tablet

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media